Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Anderson, S. Tamne, F. Droboniewski, I. Abubakar (London, United Kingdom). Factors preventing better treatment completion among MDR TB cases in a rich-resource setting. Eur Respir J 2010; 36: Suppl. 54, 2009

Member's Comments

No comment yet.

Related content which might interest you: Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Factors affecting outcomes of individualised treatment for drug resistant tuberculosis in an endemic region> Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Factors associated with completion of tuberculosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 428s Year: 2005 Success of re-treatment regime and influencing factors in patients with tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Surgical treatment for MDR TB patients – preliminary results from a Romanian MDR TB centre Source: Eur Respir J 2006; 28: Suppl. 50, 276s Year: 2006 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Impact of drug resistance among new cases on outcome of DOTS category I Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Treatment results for MDR TB patients after surgery Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 The risk factors of the TB death among case of initial treatment failure and retreatment after default Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Clinical management improves the treatment outcome of MDR-TB patients Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017